SCHEMBL1753665

SCHEMBL1753665

O=Cc1ccn(-c2ccc(Br)cc2)c(=O)c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
HTT P42858 2/20 0.39
ALOX15 P16050 1/20 0.39
ATM Q13315 1/20 0.39
FAAH O00519 1/20 0.37
MGLL Q99685 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALKBH5 Q6P6C2 1/20 0.35
PTGS2 P35354 1/20 0.34
F10 P00742 1/20 0.33
FGFR1 P11362 1/20 0.33
PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13575371 0.81 SMN1; SMN2 (0.56) ALDH1A1HTTALOX15ATMSMN1; SMN2
SCHEMBL1753478 0.80 SMN1; SMN2 (0.44) ALDH1A1HTTSMN1; SMN2MAOAMAOB
SCHEMBL1753746 0.79 HTT (0.44) ALDH1A1HTTALOX15ATMFAAH
SCHEMBL1753722 0.78 HTT (0.33) ALDH1A1HTTALOX15ATMFAAH
SCHEMBL29348799 0.74 ALDH1A1 (0.41) ALDH1A1HTTALOX15ATMFAAH
SCHEMBL10087069 0.74 HTT (0.53) ALDH1A1HTTALOX15ATMFAAH
SCHEMBL1753473 0.74 ALDH1A1 (0.41) ALDH1A1HTTALOX15ATMFAAH
SCHEMBL24408956 0.73 NR1H3 (0.36) SMN1; SMN2
SCHEMBL8107256 0.72 MGLL (0.43) ALDH1A1HTTALOX15ATMMGLL
SCHEMBL3567740 0.72 HCAR1 (0.37) ALDH1A1HTTALOX15ATMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2102208-B1 NOVEL SUBSTITUTED DIAZA SPIRO PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES JANSSEN PHARMACEUTICA NV (BE) 2014-04-23 EP disclosed
US-8158643-B2 Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases JANSSEN PHARMACEUTICA N.V. (BE) 2012-04-17 US disclosed
US-8158643-B2 Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases JANSSEN PHARMACEUTICA N.V. (BE) 2012-04-17 US disclosed
US-20100035909-A1 NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2010-02-11 US disclosed
US-20100035909-A1 NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2010-02-11 US disclosed
WO-2008068265-A1 NOVEL SUBSTITUTED DIAZA SPIRO PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2008-06-12 WO disclosed
WO-2007141200-A1 NOVEL N-ARYL AND N-HETEROARYL SUBSTITUTED PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035909-A1 NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES MCHR1, MCHR2, MC1R ALDH1A1 281/4885HTT 636/4885ALOX15 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.